Browsing: Clinical Trials & R&D

Sanofi Tolebrutinib setback includes a Phase 3 failure in primary progressive MS and a delayed US approval decision.

Arcus Gilead trial cancellation marks a setback in cancer research as the TIGIT/PD-1 study is halted for futility, impacting future strategies.

Lilly retatrutide obesity drug demonstrates up to 29% weight loss in Phase 3 study, setting a new benchmark for competitors.

Prolynx obesity drugs aim to use novel linker technology for monthly or quarterly administration, backed by a $70M Series A funding.

Novartis Ianalumab Success marks a significant achievement in treating immune thrombocytopenia, impacting low platelet counts.

Tecvayli multiple myeloma data presented at ASH suggests potential for early use in treatment, involving 165 patients.

Tern leukemia drug shows potential at ASH Conference, challenging Novartis’ Scemblix with promising early results.

Dyne Duchenne drug approval could challenge Sarepta’s Exondys 51, impacting the market and offering new clinical insights.

Lilly Jaypirca trial demonstrates efficacy comparable to Imbruvica with safety advantages, potentially altering leukemia and lymphoma treatment.

Pharvaris Phase 3 Success marks a significant milestone in hereditary angioedema treatment, potentially impacting over 8,000 patients in Europe.